On May 12th, a reporter from The Paper learned that Zhu Yi, founder, chairman, and chief scientific officer of Sichuan Baili Tianheng Pharmaceutical Co., Ltd. (Baili Tianheng, 688506), donated RMB 30 million in cash to establish the "Fudan University Baili Tianheng Distinguished Professor" project, supporting Fudan University's faculty construction needs in areas such as "innovative drug target discovery" and "brain and brain like intelligence research", and strengthening the construction and development of strategic talent teams.

Zhu Yi was born in 1963 and graduated with a bachelor's degree in Radio Physics from Sichuan University. Later, he was admitted to the Master's program in Biophysics at Fudan University and is a graduate of the Biology Department of Fudan University in 1984. Zhu Yi stated that whether it is making generic drugs or innovative drugs, there is always a knowledge framework of biology behind them. The study experience at Fudan University laid a solid foundation for himself, and this experience also cultivated his attention to details and data analysis skills.

The predecessor of Baili Tianheng founded by Zhu Yi was Baili Pharmaceutical, which was registered and established in Wenjiang, Sichuan in 1996. In 2010, Baili Tianheng shifted its focus to the development of small molecule innovative drugs and established a research and development center in Chengdu two years later. In 2014, Baili Tianheng established a research and development center SystImmune, Inc. in Seattle, USA, focusing on cutting-edge research in anti-tumor antibody drugs, including the development of innovative drugs such as bispecific antibodies and ADCs.

In January 2023, Baili Tianheng will be listed on the Science and Technology Innovation Board. In January 2025, Baili Tianheng submitted to the Hong Kong Stock Exchange. In the past two years, what has attracted the most attention in the industry for Baileys Tianheng is its transaction authorization with well-known multinational pharmaceutical companies. In December 2023, Baili Tianheng and BMS reached a cooperation agreement on the BL-B01D1 project with a down payment of 800 million US dollars and a potential total transaction value of 8.4 billion US dollars, breaking the record for Chinese innovative drugs going global. BL-B01D1 is an EGFR × HER3 dual antibody ADC under development product.

Thanks to the cooperation agreement reached with BL-B01D1, the down payment has been received and related intellectual property income has been recognized, resulting in a significant increase in Baili Tianheng's performance in 2024. The annual operating revenue reached 5.823 billion yuan, a year-on-year increase of 936.31%; The net profit attributable to the parent company and the non net profit attributable to the parent company turned around year-on-year, reaching 3.708 billion yuan and 3.636 billion yuan respectively.

Everyone only has one life, and the discovery and research of innovative drug targets have extraordinary value for living better and longer. The study of brain and brain like intelligence is of great significance for humans to explore the unknown world and answer the ultimate question of what human intelligence is. "Zhu Yi said that Fudan, as a comprehensive research university, has a very good scientific research foundation in the fields of drug target discovery and brain and brain like intelligence research, and has leading advantages in interdisciplinary research. To conduct research in cutting-edge fields, we need a group of excellent scientists and teachers. We hope that this project can support these outstanding talents to devote themselves to research at Fudan University without any worries.